Human Immunodeficiency Virus (HIV) remains one of the greatest global health challenges of our time; it is estimated that 36.7 million people are currently living with HIV globally, with at least 1.8 million more becoming newly infected each year.1 The epidemic continues to vary considerably between regions, with sub-Saharan Africa the most severely affected.
A 3D model of HIV
The world is making tremendous progress towards curbing the course of the global HIV/AIDS (acquired immune deficiency syndrome) pandemic. Since 2005, AIDS-related deaths have fallen globally by 48 percent ; and since 2010, new HIV infections in children have fallen by 47 percent.2 However, while significant progress has been made in the global fight against HIV/AIDS, there is still much more to be done to develop holistic, sustainable, and measurable solutions that deliver long-term impact.
For many, due to innovations in antiretroviral treatments (ARVs), HIV is no longer a fatal disease, but a chronic condition managed by life-long therapy. Because current therapies must be administered over the course of a life-time, the need to optimize efficacy, long-term safety, tolerability and convenience is a priority for people living with HIV and health care professionals.
One of the biggest advances in the treatment of HIV/AIDS is the development of a single-tablet regimen (STR) or combination pill – one pill that contains a combination of several HIV drugs. STRs have the potential to improve the lives of patients through simplifying dosing regimens, reducing pill burden and potentially helping to address patient non-adherence to treatment. Once-daily, single-tablet, complete HIV regimens have been shown to improve treatment adherence, patient satisfaction, and virologic outcomes compared with multi-tablet regimens.
Non-adherence to treatment remains a challenge for many people living with HIV and one of the main drivers of resistance to HIV medicines. Our hope is to make HIV treatment manageable for all by developing innovative solutions like STRs, but also long-acting regimens. Long-acting regimens may offer an effective and acceptable alternative for people who have achieved viral suppression but struggle with daily, oral regimens to control their HIV.
We continue to build on our 25-year commitment to end HIV through education, prevention, detection and treatment, so that one day we can help Make HIV History.
In partnership with patients, advocates, healthcare professionals, other leading pharmaceutical companies and scientists, we have introduced eight approved HIV medicines over the last 10 years. Our HIV medicines have helped transform the efficacy and tolerability of treatment in simplified formulations. In addition, we have further treatments currently in development, which aim to address the needs of people living with HIV, globally.
Our ultimate goal is to develop a preventive vaccine for HIV, because experts agree that this is needed to turn the tide of the HIV pandemic. The historic challenge of finding an HIV vaccine however requires global collaboration – no single organization can do it alone. Janssen has joined forces with some of the world’s leading organizations to accelerate the development of our HIV-1 preventive vaccine.
1 World Health Organization. (2017). HIV/AIDS. [online]. Available at: http://www.who.int/mediacentre/factsheets/fs360/en/ Last accessed: February 2018.
2 UNAIDS. (2017). Fact sheet - Latest statistics on the status of the AIDS epidemic. [online]. Available at: http://www.unaids.org/en/resources/fact-sheet Last accessed: February 2018.